Advanced Filters
noise

Orthostatic Hypotension Clinical Trials

A listing of Orthostatic Hypotension medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 467 clinical trials
L Lien Beullens, MSc

Visceral Sensitivity in IBD (Irritable Bowel Disease) and IBS (Irritable Bowel Syndrome)

Aim More insight in pathogenesis of IBS and IBD. Samples are collected in context of an European research project.

18 - 65 years of age Both Phase N/A
N Natasha Seaton

Acceptability of Identifying and Managing Psychological Distress in Inflammatory Bowel Disease: the COMPASS-IBD Study

This study is a single-centre, interventional implementation and feasibility study. Patients in the IBD service will be able to access COMPASS, an online cognitive-behavioural therapy (CBT) programme, as part of standard care at Guy's and St Thomas's NHS Foundation Trust. COMPASS is an online program. It will consist of 11 …

18 - 100 years of age Both Phase N/A

Study of Tolerability, Safety, and Pharmacokinetics of ZL-82 in Healthy Adult Subjects.

ZL-82 is an oral janus kinase (JAK) inhibitor. In vitro biological mass spectrometry identification test proves that ZL-82 can selectively and irreversibly inhibit JAK3. It has obvious safety advantages, with a wide therapeutic window and controllable cardiotoxicity. This is also demonstrated from preliminary GLP-conditions of acute toxicity in SD rats …

18 - 45 years of age Both Phase 1
E Eytan Wine, MD, PhD

Personalized B-fructan Diet in Inflammatory Bowel Disease Patients

This study aims to examine patient tolerability of personalized dietary fibre consumption recommendations (high-pectin diet versus high-B-fructan diet based on personalized responses), provided by an IBD dietician, based on our novel translational research findings.

6 - 39 years of age Both Phase N/A
M Marine BECK

IDENTIFICATION OF PROGNOSTIC AND PREDICTIVE BIOMARKERS IN INFLAMMATORY BOWEL DISEASE

Interventional study of a group of patients with an inflammatory bowel disease (IBD; Crohn's disease (CD) or ulcerative colitis (UC)) to identify predictive and prognostic biomarkers of natural history and response to biotherapies.

18 - 100 years of age Both Phase N/A

Translating Scientific Evidence Into Practice Using Digital Medicine and Electronic Patient Reported Outcomes

Delivery of healthcare has been traditionally limited to in-person visits or hospitalizations, while patients spend the majority of their time at home or work. Digital Medicine (e.g. apps, remote monitoring, telemedicine, patient reported outcomes) has the potential to bridge this gap, but the question remains as to how to translate …

18 - 100 years of age Both Phase N/A

A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC

This is a Phase 2b randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of three active dose regimens of MORF-057 in adult patients with moderately to severely active Ulcerative Colitis (UC).

18 - 85 years of age Both Phase 2

ENhanced Recovery in CHildren Undergoing Surgery

The institution of perioperative Enhanced Recovery Protocols (ERPs) has been found to decrease hospital length of stay, in-hospital costs, and complications among adult surgical populations but data in pediatric populations are lacking. The Assessing Effectiveness and Implementation of a Perioperative Enhanced Recovery Protocol for Children Undergoing Gastrointestinal Surgery, which has …

10 - 18 years of age Both Phase 3

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will last about 172 weeks and may include up to 44 visits.

2 - 19 years of age Both Phase 3

The Nordic IBD Treatment Strategy Trial

Purpose To demonstrate that personalised therapy can be delivered to patients with IBD, by treating patients with an increased risk of poor disease course, defined by a serum protein signature at diagnosis, with a top-down treatment, and that this treatment strategy improves clinical outcomes. Objectives Primary objective: To assess if …

18 - 70 years of age Both Phase 4

Rewrite in simple language using AI